Gritstone Oncology will leverage its proprietary EDGE artificial intelligence platform to analyze specific tumor types to identify tumor-specific targets and natural T-cell receptors (TCRs) directed to those targets
The company will invest a double-digit million-euro figure to add another 50 percent to its existing capacity. The new production lines will be installed at the company’s syringe
The Comfort Phase III Psoriasis study, is designed to evaluate the efficacy and safety of daily Piclidenoson, administered orally compared to Apremilast (Otezla) and placebo, in 407 patients
As per the research published in Nature Communications, the scientists at the University of Cambridge discovered that a protein called BCL11A is found in high amounts in lung
The global partnership, which will exclude the Greater China region, is expected to fetch more than $350m to Kelun-Biotech in addition to royalties based on annual net sales.
The randomized, double-blind, placebo-controlled Phase 2 study will be conducted across 50 sites in Europe, the U.S., Canada, Israel, and Turkey, and enroll approximately 260 patients. The Company
In their study in mice, the scientists discovered that liver injury triggered senescence, which is normally associated with aging or chronic disease. The researchers found that certain anti-cancer
The study, the first programme under Immunocore’s collaboration with GSK to proceed into clinical development, will assess the safety and tolerability of IMCnyeso in patients with non-small cell
At the week 16 primary efficacy analysis, the study met both co-primary endpoints and all key secondary endpoints. Fasinumab-treated patients experienced significantly less pain and significantly improved functional
CEQUA is indicated to increase tear production in patients with keratoconjunctivitis sicca (dry eye). CEQUA provides the highest FDA-approved concentration of cyclosporine A (CsA) and is the first
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.